Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × Radiation × 30 days × Clear all

NCT06583837 2026-02-27

Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell, Marginal Zone